The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder : a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis
© 2023. The Author(s)..
BACKGROUND: Major depressive disorder causes a great burden on patients and societies. Venlafaxine and mirtazapine are commonly prescribed as second-line treatment for patients with major depressive disorder worldwide. Previous systematic reviews have concluded that venlafaxine and mirtazapine reduce depressive symptoms, but the effects seem small and may not be important to the average patient. Moreover, previous reviews have not systematically assessed the occurrence of adverse events. Therefore, we aim to investigate the risks of adverse events with venlafaxine or mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder in two separate systematic reviews.
METHODS: This is a protocol for two systematic reviews with meta-analysis and Trial Sequential Analysis. The assessments of the effects of venlafaxine or mirtazapine will be reported in two separate reviews. The protocol is reported as recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, risk of bias will be assessed with the Cochrane risk-of-bias tool version 2, clinical significance will be assessed using our eight-step procedure, and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach. We will search for published and unpublished trials in major medical databases and trial registers. Two review authors will independently screen the results from the literature searches, extract data, and assess risk of bias. We will include published or unpublished randomised clinical trial comparing venlafaxine or mirtazapine with 'active placebo', placebo, or no intervention for adults with major depressive disorder. The primary outcomes will be suicides or suicide attempts, serious adverse events, and non-serious adverse events. Exploratory outcomes will include depressive symptoms, quality of life, and individual adverse events. If feasible, we will assess the intervention effects using random-effects and fixed-effect meta-analyses.
DISCUSSION: Venlafaxine and mirtazapine are frequently used as second-line treatment of major depressive disorder worldwide. There is a need for a thorough systematic review to provide the necessary background for weighing the benefits against the harms. This review will ultimately inform best practice in the treatment of major depressive disorder.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022315395.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Systematic reviews - 12(2023), 1 vom: 30. März, Seite 57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jørgensen, Caroline Kamp [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7D7RX5A8MO |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 12.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13643-023-02221-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354964437 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354964437 | ||
| 003 | DE-627 | ||
| 005 | 20231226063343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13643-023-02221-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM354964437 | ||
| 035 | |a (NLM)36991504 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jørgensen, Caroline Kamp |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder |b a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Major depressive disorder causes a great burden on patients and societies. Venlafaxine and mirtazapine are commonly prescribed as second-line treatment for patients with major depressive disorder worldwide. Previous systematic reviews have concluded that venlafaxine and mirtazapine reduce depressive symptoms, but the effects seem small and may not be important to the average patient. Moreover, previous reviews have not systematically assessed the occurrence of adverse events. Therefore, we aim to investigate the risks of adverse events with venlafaxine or mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder in two separate systematic reviews | ||
| 520 | |a METHODS: This is a protocol for two systematic reviews with meta-analysis and Trial Sequential Analysis. The assessments of the effects of venlafaxine or mirtazapine will be reported in two separate reviews. The protocol is reported as recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, risk of bias will be assessed with the Cochrane risk-of-bias tool version 2, clinical significance will be assessed using our eight-step procedure, and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach. We will search for published and unpublished trials in major medical databases and trial registers. Two review authors will independently screen the results from the literature searches, extract data, and assess risk of bias. We will include published or unpublished randomised clinical trial comparing venlafaxine or mirtazapine with 'active placebo', placebo, or no intervention for adults with major depressive disorder. The primary outcomes will be suicides or suicide attempts, serious adverse events, and non-serious adverse events. Exploratory outcomes will include depressive symptoms, quality of life, and individual adverse events. If feasible, we will assess the intervention effects using random-effects and fixed-effect meta-analyses | ||
| 520 | |a DISCUSSION: Venlafaxine and mirtazapine are frequently used as second-line treatment of major depressive disorder worldwide. There is a need for a thorough systematic review to provide the necessary background for weighing the benefits against the harms. This review will ultimately inform best practice in the treatment of major depressive disorder | ||
| 520 | |a SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022315395 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse effects | |
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a Antidepressants | |
| 650 | 4 | |a Beneficial effects | |
| 650 | 4 | |a Major depressive disorder | |
| 650 | 4 | |a Mirtazapine | |
| 650 | 4 | |a Venlafaxine | |
| 650 | 7 | |a Mirtazapine |2 NLM | |
| 650 | 7 | |a A051Q2099Q |2 NLM | |
| 650 | 7 | |a Venlafaxine Hydrochloride |2 NLM | |
| 650 | 7 | |a 7D7RX5A8MO |2 NLM | |
| 700 | 1 | |a Juul, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Siddiqui, Faiza |e verfasserin |4 aut | |
| 700 | 1 | |a Horowitz, Mark Abie |e verfasserin |4 aut | |
| 700 | 1 | |a Moncrieff, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Munkholm, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Hengartner, Michael Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Kirsch, Irving |e verfasserin |4 aut | |
| 700 | 1 | |a Gluud, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Jakobsen, Janus Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Systematic reviews |d 2012 |g 12(2023), 1 vom: 30. März, Seite 57 |w (DE-627)NLM217806902 |x 2046-4053 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |g day:30 |g month:03 |g pages:57 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13643-023-02221-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 |b 30 |c 03 |h 57 | ||